The efficacy of intravenously administered tiapamil in treating premature ventricular contractions (PVCs) in the acute phase of acute myocardial infarction was evaluated in 20 patients using 24-hour continuous ECG monitoring (Holier). All patients presented frequent and/or complex ventricular arrhythmias (Lown classification II-V). Tiapamil reduced the number of PVCs to a statistically highly significant degree (p < 0.01), i.e. 82-85% in the 4th hour of treatment. The number of PVCs increased again after therapy was discontinued. Where supraventricular ectopic beats were present in addition to PVCs, tiapamil reduced them by 93% in the 3rd and 4th hours of treatment. These results suggest that tiapamil could be an effective antiarrhythmic agent in acute myocardial infarction.

No abstract

Due to the rising prevalence of coronary heart disease, endoscopists are more frequently performing a polypectomy in patients on antiplatelet therapy (APT) and dual antiplatelet therapy (DATP). Despite the availability of several guidelines with regard to the management of antiplatelet drugs during the periprocedure period, there is still variability in the current clinical practice. This may be influenced by the low quality of the evidence supporting recommendations, because most of the studies dealing with APT and polypectomy are observational and retrospective, and include mainly small (< 10 mm) polyps. However, some recommendations can still be made. An estimation of the bleeding and thrombotic risk of the patient should be made in advance. In the case of DAPT the procedure should be postponed, at least until clopidogrel can be safely withheld. If possible, non-aspirin antiplatelet drugs should be withheld 5-7 days before the procedure. Polyp size is the main factor related with post-polypectomy bleeding and it is the factor that should drive clinical decisions regarding the resection method and the use of endoscopic prophylactic measures. Non-aspirin antiplatelet agents can be reintroduced 24-48 hours after the procedure. In conclusion, there is little data with regard to the management of DAPT in patients with a scheduled polypectomy. Large randomized controlled trials are needed to support clinical recommendations.